

## Neoadjuvant Treatment

GUIDELINE	DOCUMENT	ORGANISATION / COUNTRY	YEAR PUBLISHED
Neoadjuvant therapy	<b>Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)</b>	National Institute for Health and Care Excellence (NICE), UK	2016
<p>Comments:</p> <p>This guidance re-emphasises the importance of discussing all ER-ve and HER2+ve breast cancer patients in the pre-operative MDT.</p>			

<b>Date:</b>	February 2018
<b>Version:</b>	1

The guideline title in the document column includes a hyperlink to the relevant guideline. Please view the document on the ABS website to follow these links.